EP1242107A4 - Method for pr-39 peptide mediated selective inhibition of ikappabalpha degradation - Google Patents

Method for pr-39 peptide mediated selective inhibition of ikappabalpha degradation

Info

Publication number
EP1242107A4
EP1242107A4 EP00989492A EP00989492A EP1242107A4 EP 1242107 A4 EP1242107 A4 EP 1242107A4 EP 00989492 A EP00989492 A EP 00989492A EP 00989492 A EP00989492 A EP 00989492A EP 1242107 A4 EP1242107 A4 EP 1242107A4
Authority
EP
European Patent Office
Prior art keywords
selective inhibition
peptide mediated
mediated selective
ikappabalpha
degradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00989492A
Other languages
German (de)
French (fr)
Other versions
EP1242107A1 (en
Inventor
Michael Simons
Youhe Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/474,967 external-priority patent/US7169604B1/en
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Publication of EP1242107A1 publication Critical patent/EP1242107A1/en
Publication of EP1242107A4 publication Critical patent/EP1242107A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP00989492A 1999-12-29 2000-12-27 Method for pr-39 peptide mediated selective inhibition of ikappabalpha degradation Withdrawn EP1242107A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/474,967 US7169604B1 (en) 1998-10-13 1999-12-29 Method for PR-39 peptide mediated selective inhibition of IκBα degradation
US474967 1999-12-29
PCT/US2000/035293 WO2001047540A1 (en) 1999-12-29 2000-12-27 METHOD FOR PR-39 PEPTIDE MEDIATED SELECTIVE INHIBITION OF IλBα DEGRADATION

Publications (2)

Publication Number Publication Date
EP1242107A1 EP1242107A1 (en) 2002-09-25
EP1242107A4 true EP1242107A4 (en) 2004-10-06

Family

ID=23885707

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00989492A Withdrawn EP1242107A4 (en) 1999-12-29 2000-12-27 Method for pr-39 peptide mediated selective inhibition of ikappabalpha degradation

Country Status (4)

Country Link
EP (1) EP1242107A4 (en)
AU (1) AU2599001A (en)
CA (1) CA2397955A1 (en)
WO (1) WO2001047540A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261652A1 (en) * 2002-07-31 2004-02-23 Charite-Universitatsmedizin Berlin Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
ES2426441T3 (en) 2004-10-18 2013-10-23 Basf Beauty Care Solutions France S.A.S. Oligopeptides and their use in cosmetics
US7939499B2 (en) 2005-05-03 2011-05-10 Trustees Of Dartmouth College Method for increasing cardiac mass and performance

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489575A (en) * 1991-06-14 1996-02-06 Hans G. Boman Polypeptides and their use
WO1996032129A1 (en) * 1995-04-10 1996-10-17 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
WO1998035690A1 (en) * 1997-02-18 1998-08-20 Kansas State University Research Foundation Peptide modulation of reperfusion injury
WO2000057895A1 (en) * 1999-03-26 2000-10-05 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
WO2001030368A1 (en) * 1999-10-25 2001-05-03 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489575A (en) * 1991-06-14 1996-02-06 Hans G. Boman Polypeptides and their use
WO1996032129A1 (en) * 1995-04-10 1996-10-17 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
WO1998035690A1 (en) * 1997-02-18 1998-08-20 Kansas State University Research Foundation Peptide modulation of reperfusion injury
WO2000057895A1 (en) * 1999-03-26 2000-10-05 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
WO2001030368A1 (en) * 1999-10-25 2001-05-03 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GAO Y ET AL: "Inhibition of ubiquitin-proteasome pathway-mediated I-kappaBalpha degradation by a naturally occuring antibacterial peptide", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 106, no. 3, August 2000 (2000-08-01), pages 439 - 448, XP002180614, ISSN: 0021-9738 *
GAO YOUHE ET AL: "PR39 interacts with proteasome and modulates HIF-1alpha level in ECV cells", MOLECULAR BIOLOGY OF THE CELL, vol. 9, no. SUPPL., November 1998 (1998-11-01), & 38TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY; SAN FRANCISCO, CALIFORNIA, USA; DECEMBER 12-16, 1998, pages 123A, XP008033931, ISSN: 1059-1524 *
HOFFMEYER M R ET AL: "PR-39, a potent neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice.", AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY. DEC 2000, vol. 279, no. 6, December 2000 (2000-12-01), pages H2824 - H2828, XP002292143, ISSN: 0363-6135 *
LI J ET AL: "CARDIAC-SPECIFIC OVEREXPRESSION OF PR-39 INDUCES ANGIOGENESIS, MYOCARDIAL HYPERTROPHY AND INCREASED MICROVASCULAR REACTIVITY", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 98, no. 17, October 1998 (1998-10-01), pages 1794, XP002929855, ISSN: 0009-7322 *
LI J ET AL: "Macrophage-dependent regulation of syndecan gene expression", CIRCULATION RESEARCH 1997 UNITED STATES, vol. 81, no. 5, 1997, pages 785 - 796, XP008033955, ISSN: 0009-7330 *
LI J ET AL: "PR39, a peptide regulator of angiogenesis", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 6, no. 1, January 2000 (2000-01-01), pages 49 - 55, XP002968105, ISSN: 1078-8956 *
See also references of WO0147540A1 *

Also Published As

Publication number Publication date
WO2001047540A1 (en) 2001-07-05
EP1242107A1 (en) 2002-09-25
AU2599001A (en) 2001-07-09
CA2397955A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
PL346317A1 (en) Method for administering insulinotropic peptides
IL141553A0 (en) Drug preparations for treating sexual dysfunction
AU2913701A (en) System and method for facilitating selection of benefits
EP1055371A4 (en) Method for treatment of containerised food
AU1604501A (en) System and method for removal of material
GB0010276D0 (en) Method of forming films
EP1143953A3 (en) Method of inhibiting angiogenesis
IL146529A0 (en) Method of inhibiting neurotrophin-receptor binding
HUP0200079A3 (en) Treatment of infertility
GB2354409B (en) System for elimination of audible effects of handover
EP1009199A4 (en) Method for controlling plasma processor
GB2353684B (en) Method for automatically switching windows of different sizes
EP1165111A4 (en) Method for pr-39 peptide regulated stimulation of angiogenesis
EP1242107A4 (en) Method for pr-39 peptide mediated selective inhibition of ikappabalpha degradation
AU2354800A (en) Method of protein removal
AU5898200A (en) Improved system for treating meat
EP1232159A4 (en) Beta-amyloid peptide inhibitors
GB9610488D0 (en) Protection means for freezing process
IL126671A0 (en) Drug preferably for inhibiting inflammation
IL144762A0 (en) Liposome composition and method for administration of radiosensitizer
AU8651298A (en) Inhibition of unwanted hormone action in plants
IL150485A0 (en) Method of achieving persistent transgene expression
AU6600400A (en) Methods and means for inhibiting angiogenesis
EP1012172A4 (en) Acylated peptide cytolytic peptide inhibitors
IL129669A0 (en) Ice inhibiting peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

A4 Supplementary search report drawn up and despatched

Effective date: 20040824

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/47 B

Ipc: 7A 61K 38/16 B

Ipc: 7C 07K 7/06 B

Ipc: 7C 07K 7/00 B

Ipc: 7A 61K 38/00 A

Ipc: 7C 07K 7/04 B

17Q First examination report despatched

Effective date: 20050425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050906